Dr. Anupama D. Kumar, M.D.
Internal Medicine (Internal Medicine Physician)
3855 Health Sciences Dr
La Jolla, CA 92093
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Tufts University School of Medicine (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 146
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: Tufts University School of Medicine
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
CA license 277740 · MA license 267215
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UCSF Medical Center San Francisco, CA
Medical groups
- University of California San Francisco (1,839 clinicians)
- UCSF Medical Group Business Services (1,598 clinicians)
- Regents of the University of California (732 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 146
- Services billed
- 4,600
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 63 | 53 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Revlimid (lenalidomide) | 83 |
| Acyclovir Other prescribers in La Jolla, CA | 65 |
| Pomalyst (pomalidomide) | 49 |
| Oxycodone Hcl Other prescribers in La Jolla, CA | 30 |
| Allopurinol Other prescribers in La Jolla, CA | 22 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in La Jolla, CA | 16 |
| Ondansetron Odt (ondansetron) Other prescribers in La Jolla, CA | 12 |
| Omeprazole Other prescribers in La Jolla, CA | 12 |
| Tramadol Hcl Other prescribers in La Jolla, CA | 12 |
| Ninlaro (ixazomib citrate) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 17 payments worth $14,354 in total to this clinician.
| Janssen Global Services, LLC | $9,768 |
|---|---|
| AstraZeneca UK Limited | $2,355 |
| Legend Biotech USA Inc. | $1,799 |
| Janssen Biotech, Inc. | $267 |
| AstraZeneca Pharmaceuticals LP | $135 |
| Pfizer Inc. | $29.99 |
| Consulting Fee | $13,538 |
|---|---|
| Food and Beverage | $744 |
| Travel and Lodging | $72.03 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Global Services, LLC Dec 4, 2025 | Consulting Fee CARVYKTI · Oncology | $2,900 |
| Janssen Global Services, LLC Dec 6, 2025 | Consulting Fee CARVYKTI · Oncology | $2,538 |
| Janssen Global Services, LLC Jul 15, 2025 | Consulting Fee CARVYKTI · Oncology | $2,450 |
| AstraZeneca UK Limited Dec 12, 2025 | Consulting Fee | $2,250 |
| Janssen Global Services, LLC Aug 14, 2025 | Consulting Fee CARVYKTI · Oncology | $1,750 |
| Legend Biotech USA Inc. Dec 12, 2025 | Consulting Fee CARVYKTI · Oncology | $1,650 |
| Legend Biotech USA Inc. Aug 9, 2025 | Travel and Lodging travel to Seattle, WA · in-kind | $39.04 |
| Legend Biotech USA Inc. Aug 9, 2025 | Travel and Lodging travel to Seattle, WA · in-kind | $32.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $411,211 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Celgene Corporation - A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants with High-Risk Multiple Myeloma
Janssen Research & Development, LLC - A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma
AstraZeneca Pharmaceuticals LP - A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, …
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.